Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach

The use of novel B-cell receptor signaling inhibitors results in high response rates and long progression-free survival in patients with indolent B-cell malignancies, such as chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinemia. Ibrutinib, the fir...

Full description

Saved in:

Bibliographic Details
Published in:	Haematologica (Roma) Vol. 102; no. 10; pp. 1629 - 1639
Main Authors:	de Weerdt, Iris, Koopmans, Suzanne M., Kater, Arnon P., van Gelder, Michel
Format:	Journal Article
Language:	English
Published:	Italy Ferrata Storti Foundation 01.10.2017
Subjects:	Agammaglobulinaemia Tyrosine Kinase Antineoplastic Agents - adverse effects Disease Management Drug Interactions Drug-Related Side Effects and Adverse Reactions - diagnosis Drug-Related Side Effects and Adverse Reactions - epidemiology Drug-Related Side Effects and Adverse Reactions - etiology Drug-Related Side Effects and Adverse Reactions - therapy Humans Incidence Leukemia, Lymphocytic, Chronic, B-Cell - complications Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Lymphoma, B-Cell - complications Lymphoma, B-Cell - drug therapy Protein Kinase Inhibitors - adverse effects Protein-Tyrosine Kinases - antagonists & inhibitors Purines - administration & dosage Purines - adverse effects Pyrazoles - administration & dosage Pyrazoles - adverse effects Pyrimidines - administration & dosage Pyrimidines - adverse effects Quinazolinones - administration & dosage Quinazolinones - adverse effects Review Severity of Illness Index
ISSN:	0390-6078, 1592-8721, 1592-8721
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!